OTL38 was approved by the FDA in 2021 as Pafolacianine after its Phase III clinical trials for the intraoperative identification, imaging and resection of FRα positive ovarian and lung cancers provided promising clinical data36,37. The gene discussed is FOLR1; the disease is lung carcinoma.